TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33770291

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 3
Study: 33770527

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Activities of Daily Living (ADL)
Number of subjects: 602
Study: 33770575

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg orally on days 1-21 of a 28-day cycle)
Number of subjects: 15
Study: 33770779

Group type: EXPERIMENTAL
Intervention: Riemannian spatial pattern method
Number of subjects: 0
Study: 33770805

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injection (100 units)
Number of subjects: 237
Study: 33771219

Group type: EXPERIMENTAL
Intervention: Dietary intake of poorer-quality food items during main meals
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Gut microbiota analysis
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Exhaled gas levels and symptom severity prediction
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Covariations between gut microbiota and diet
Number of subjects: 149
Study: 33771233

Group type: EXPERIMENTAL
Intervention: HENRY intervention (Health, Exercise and Nutrition for the Really Young)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cluster randomisation
Number of subjects: 51

Group type: COMPARATOR
Intervention: Recommendations for public health intervention trials
Number of subjects: 51
Study: 33771287

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 283

Group type: COMPARATOR
Intervention: Non-opioid detoxification
Number of subjects: 283
Study: 33771694

Group type: EXPERIMENTAL
Intervention: Gonadal development and maturation (activation of the HPG-axis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal repeated-measures sampling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocrine measures collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI activation and resting-state networks
Number of subjects: 0
Study: 33771703

Group type: EXPERIMENTAL
Intervention: DE-Un
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: DE-Mth
Number of subjects: 75

Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 75
Study: 33771853

Group type: EXPERIMENTAL
Intervention: Evofosfamide (400-640 mg/m2) in combination with Ipilimumab
Number of subjects: 22
Study: 33771885

Group type: EXPERIMENTAL
Intervention: Enzalutamide/abiraterone
Number of subjects: 48
Study: 33772397

Group type: EXPERIMENTAL
Intervention: Intraoral neuromuscular stimulation device (NMES), used for 20 min once daily for a 6-week period.
Number of subjects: 70
Study: 33772428

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment (including Factor Xa inhibitors/direct thrombin inhibitors and antiplatelet therapy)
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Factor Xa inhibitors/direct thrombin inhibitors
Number of subjects: 1660

Group type: EXPERIMENTAL
Intervention: Factor Xa/DTI + APs
Number of subjects: 1660
Study: 33772591

Group type: EXPERIMENTAL
Intervention: Insomnia patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study: 33772822

Group type: EXPERIMENTAL
Intervention: Handheld smartphone ECG (iECG)
Number of subjects: 115
Study: 33773011

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33773200

Group type: EXPERIMENTAL
Intervention: Self-reported sleep efficiency on heavier-drinking days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Self-reported alcohol use following days of better sleep efficiency
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Subjective sleep efficiency
Number of subjects: 56

Group type: COMPARATOR
Intervention: Objective measures of sleep efficiency
Number of subjects: 56
Study: 33773443

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33773598

Group type: COMPARATOR
Intervention: Aβ-negative subjects
Number of subjects: 686

Group type: COMPARATOR
Intervention: Subjects in the 'gray zone'
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Subjects with established Aβ pathology (MCI)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Aβ-negative subjects and gray zone subjects
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Cutoffs for amyloid PET abnormality
Number of subjects: 686
Study: 33774438

Group type: EXPERIMENTAL
Intervention: Intraoperative BDNF serum levels
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intraoperative BDNF serum levels (T2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intraoperative BDNF serum levels (T4)
Number of subjects: 45
Study: 33774669

Group type: EXPERIMENTAL
Intervention: MTX optimization (72% of patients)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: bDMARD initiation ± MTX (16% of patients)
Number of subjects: 722
Study: 33774745

Group type: EXPERIMENTAL
Intervention: Eculizumab and mycophenolate mofetil (MMF)
Number of subjects: 2
Study: 33774767

Group type: EXPERIMENTAL
Intervention: TAS0728 at 200 mg BID
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TAS0728 at 150 mg BID
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: TAS0728 treatment response
Number of subjects: 19
Study: 33774800

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serial changes in interelectrode conduction times
Number of subjects: 100
Study: 33775123

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor receptor inhibition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33775127

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 0
Study: 33775523

Group type: EXPERIMENTAL
Intervention: Galsulfase enzyme replacement therapy (ERT)
Number of subjects: 3
Study: 33776633

Group type: EXPERIMENTAL
Intervention: Active treatment group (6 months treatment)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study: 33776798

Group type: EXPERIMENTAL
Intervention: Virtual exercise program from 8-10 to 38-39 weeks of pregnancy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 72
Study: 33776891

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33776910

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 306

Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Diabetic non-survivors
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Diabetic survivors
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Non-survival diabetic cases
Number of subjects: 306
Study: 33776922

Group type: EXPERIMENTAL
Intervention: T2DM group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study: 33776937

Group type: EXPERIMENTAL
Intervention: Lower plasma albumin concentration
Number of subjects: 0
Study: 33777758

Group type: EXPERIMENTAL
Intervention: 38.5 Gy IMRT or 3D-CRT APBI w/3.85 Gy fraction/BID fractionation for 10 fractions
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Triple negative and ER- statuses
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Triple negative type
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Overall survival for all patients
Number of subjects: 269
Study: 33778020

Group type: EXPERIMENTAL
Intervention: Algorithmic interpretation of FFR pullback curves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33778051

Group type: EXPERIMENTAL
Intervention: PD-L1 analysis from pleural effusion
Number of subjects: 0
Study: 33778150

Group type: EXPERIMENTAL
Intervention: Sargramostim
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 33778174

Group type: EXPERIMENTAL
Intervention: Quantitative ultrasound (QUS) during radical radiotherapy (RT) (70 Gy/33 fractions)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: QUS Delta-radiomics
Number of subjects: 51
Study: 33778551

Group type: EXPERIMENTAL
Intervention: Aortic strain measurement at the distal descending aorta (DDA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aortic strain measurement at the ascending aorta (AA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pulse wave velocity (PWV) measurement
Number of subjects: 45
Study: 33778621

Group type: EXPERIMENTAL
Intervention: MRI examinations
Number of subjects: 532
Study: 33778911

Group type: EXPERIMENTAL
Intervention: Sarcopenia-related factors (lower body function, handgrip strength, gait speed, appendicular skeletal muscle mass index-ASMI)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Lower body function
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Physical fitness (upper-and-lower-body strength, agility/dynamic balance, cardiorespiratory fitness, body mass index)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Habitual physical activity
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Independence in activities of daily living (ADL)
Number of subjects: 115
Study: 33778928

Group type: EXPERIMENTAL
Intervention: Etrolizumab autoinjector (AI) 105 mg
Number of subjects: 30
Study: 33778934

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy subjects (normal renal function)
Number of subjects: 45
Study: 33779291

Group type: EXPERIMENTAL
Intervention: Resveratrol-paclitaxel-coated peripheral balloon catheter
Number of subjects: 784
Study: 33779541

Group type: EXPERIMENTAL
Intervention: Sleep fragmentation (SF) as measured by sleep fragmentation index (SFI), arousal index (ArI), sleep efficiency (SE), and wake after sleep onset (WASO)
Number of subjects: 4887

Group type: EXPERIMENTAL
Intervention: Sleep efficiency (SE)
Number of subjects: 4887
Study: 33779567

Group type: EXPERIMENTAL
Intervention: Diabetes Engagement and Activation Platform (DEAP) - automated patient education tool; all 189 intervention patients accessed the first module, and 140 patients (74.1%) accessed all 9 modules.
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Intervention group (DEAP)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 337
Study: 33779569

Group type: EXPERIMENTAL
Intervention: Telehealth Transition Assistance Program (TAP) for caregivers of individuals with acute SCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 0
Study: 33779799

Group type: EXPERIMENTAL
Intervention: OCT imaging and clinical factors
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lower birthweight
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clinical factors (GA, birthweight, PMA, sex, race, multiparity, maximum ROP stage, OCT features)
Number of subjects: 66
Study: 33779850

Group type: EXPERIMENTAL
Intervention: Side lying position
Number of subjects: 12

Group type: COMPARATOR
Intervention: Seated position
Number of subjects: 12

Group type: COMPARATOR
Intervention: Squatting position
Number of subjects: 12
Study: 33779887

Group type: EXPERIMENTAL
Intervention: Higher baseline cardiovascular fitness
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Higher baseline muscular strength
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Aerobic and/or strength training interventions
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Chemotherapy completion (RDI ≥ 85%)
Number of subjects: 543
Study: 33779986

Group type: COMPARATOR
Intervention: Heparin versus no treatment/placebo
Number of subjects: 3839

Group type: EXPERIMENTAL
Intervention: LMWH versus UFH
Number of subjects: 3839

Group type: COMPARATOR
Intervention: UFH versus no treatment
Number of subjects: 3839

Group type: COMPARATOR
Intervention: Heparin versus placebo
Number of subjects: 3839

Group type: COMPARATOR
Intervention: LMWH versus no treatment/placebo
Number of subjects: 3839
Study: 33780567

Group type: EXPERIMENTAL
Intervention: Single-dose, long-acting intravenous dalbavancin
Number of subjects: 309

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 309
Study: 33780662

Group type: EXPERIMENTAL
Intervention: Furmonertinib 80 mg orally once daily
Number of subjects: 220
Study: 33781087

Group type: EXPERIMENTAL
Intervention: Breastfeeding as an infant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not breastfed as an infant
Number of subjects: 0
Study: 33781352

Group type: EXPERIMENTAL
Intervention: Collaborative Decision Skills Training (CDST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptation Resource Team process
Number of subjects: 0
Study: 33781677

Group type: EXPERIMENTAL
Intervention: Scoreflex NC scoring angioplasty catheter
Number of subjects: 200
Study: 33781934

Group type: EXPERIMENTAL
Intervention: Scoring tool for systemic symptoms during aspirin challenge
Number of subjects: 0
Study: 33781957

Group type: EXPERIMENTAL
Intervention: LMC-based Fizyosoft® HandROM System
Number of subjects: 35

Group type: COMPARATOR
Intervention: Universal goniometer
Number of subjects: 35
Study: 33781988

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion targets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33782021

Group type: COMPARATOR
Intervention: Occupations characterised by being mostly sedentary (ISCO group 1-4)
Number of subjects: 11474

Group type: EXPERIMENTAL
Intervention: Occupations with primarily physical demanding work (ISCO group 5-9)
Number of subjects: 11474

Group type: EXPERIMENTAL
Intervention: Female workers
Number of subjects: 11474
Study: 33782211

Group type: EXPERIMENTAL
Intervention: Gamma Irradiation (GI) at a target dose of 50 kGy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-Gamma Irradiation (non-GI)
Number of subjects: 48
Study: 33782300

Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study: 33782310

Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up 68Ga-FAPI PET/CT
Number of subjects: 1

Group type: COMPARATOR
Intervention: 18F-FDG PET/CT
Number of subjects: 1
Study: 33782906

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss program (adapted)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Racial discrimination (group-level)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Racial identity-centrality (among NHB women)
Number of subjects: 49
Study: 33782940

Group type: COMPARATOR
Intervention: Any weight loss intervention
Number of subjects: 988

Group type: COMPARATOR
Intervention: Surgical interventions
Number of subjects: 988

Group type: COMPARATOR
Intervention: Non-surgical weight loss interventions
Number of subjects: 988
Study: 33782956

Group type: EXPERIMENTAL
Intervention: Omalizumab (XOLAIR) from baseline to week 16 and mOIT from week 8 to week 36
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33783067

Group type: EXPERIMENTAL
Intervention: BCNU (150 mg/m²) and temozolomide
Number of subjects: 55
Study: 33783145

Group type: EXPERIMENTAL
Intervention: Powered wearable exoskeleton (H-MEX) training, 60 minutes, 3 times per week for 10 weeks (total 30 sessions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Powered wearable exoskeleton (H-MEX) training
Number of subjects: 10
Study: 33783269

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for COVID-19-associated respiratory failure
Number of subjects: 32
Study: 33783375

Group type: EXPERIMENTAL
Intervention: 7-day low-salt diet (3.0 g/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7-day high-salt diet (18 g/day)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SNP rs12042763
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SNP rs2861813
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SNP rs2294654
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: SNP rs718067
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Gene-based analysis of Pappa2
Number of subjects: 80
Study: 33783425

Group type: EXPERIMENTAL
Intervention: TRM program intervention
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Purgative containing polyethylene glycol
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Men
Number of subjects: 2104
Study: 33783498

Group type: EXPERIMENTAL
Intervention: Rituximab (200, 500, 700, and 1000 mg single intravenous dose)
Number of subjects: 24
Study: 33783586

Group type: EXPERIMENTAL
Intervention: Maternal late-pregnancy consumption of gluten-containing foods
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Maternal late-pregnancy consumption of selected foods (non-gluten cereals, fresh milk, sour milk, cheese products, soy products, lean/medium-fat fish, fatty fish)
Number of subjects: 8556

Group type: EXPERIMENTAL
Intervention: Maternal gluten-containing food consumption by country
Number of subjects: 8556
Study: 33783691

Group type: EXPERIMENTAL
Intervention: Monaco criteria
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CRM criteria
Number of subjects: 40
Study: 33783815

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 158
Study: 33783955

Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Presence of anxiety/depression
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Older age, higher total cholesterol, HbA1c, waist circumference, waist-to-height ratio, moderately increased albumin-creatinine ratio, stroke/transient ischaemic attack, and retinal disease
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Higher years at education completion, baseline cognitive function, taller stature, and current alcohol use
Number of subjects: 11140

Group type: EXPERIMENTAL
Intervention: Sex differences in risk factors
Number of subjects: 11140
Study: 33784265

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1252

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 1252
Study: 33784394

Group type: EXPERIMENTAL
Intervention: 8-week vegan diet
Number of subjects: 23
Study: 33784416

Group type: EXPERIMENTAL
Intervention: High PEEP
Number of subjects: 3851
Study: 33784963

Group type: EXPERIMENTAL
Intervention: Modified fixed citrate concentration protocol (fixed protocol)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Titrated protocol (historical control)
Number of subjects: 66
Study: 33785064

Group type: EXPERIMENTAL
Intervention: ICU follow-up clinic intervention including information, consultation, and networking components.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 100
Study: 33785220

Group type: EXPERIMENTAL
Intervention: Xpert Test positive
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Xpert Test
Number of subjects: 254
Study: 33785324

Group type: EXPERIMENTAL
Intervention: Phytochemical-enriched low-nitrite meat diet
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Poultry diet
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nitrate-enriched water
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional processed meats and low-nitrite processed meat diets
Number of subjects: 63
Study: 33785483

Group type: EXPERIMENTAL
Intervention: SINE compounds in combination with R-CHOP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SINE compounds
Number of subjects: 0
Study: 33785489

Group type: EXPERIMENTAL
Intervention: Model 1: Enhanced provision
Number of subjects: 226

Group type: COMPARATOR
Intervention: Model 2: Independent provision
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 226
Study: 33785495

Group type: EXPERIMENTAL
Intervention: Individuals with persistent symptoms following recovery from acute SARS-CoV-2 infection
Number of subjects: 201

Group type: COMPARATOR
Intervention: Hospitalisation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Severe post-COVID-19 syndrome
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Mild organ impairment
Number of subjects: 201
Study: 33785590

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICAM-1 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optical imaging and PET using near-infrared fluorescence dye
Number of subjects: 0
Study: 33785610

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC)
Number of subjects: 112
Study: 33785784

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 RNAemia (RNAemia) defined as RNA copies above 1000/ml measured by PCR in plasma
Number of subjects: 92

Group type: COMPARATOR
Intervention: Patients without RNAemia
Number of subjects: 92
Study: 33786329

Group type: COMPARATOR
Intervention: Low-Molecular Weight Hyaluronic Acid (LMW-HA); n = 14; 3 weekly intra-articular injections.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP); n = 19; 3 weekly intra-articular injections.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: LP-PRP
Number of subjects: 34
Study: 33786412

Group type: EXPERIMENTAL
Intervention: GI-4000, a recombinant yeast expressing mutated RAS proteins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33786454

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 1090

Group type: COMPARATOR
Intervention: No Rituximab
Number of subjects: 1090
Study: 33786517

Group type: EXPERIMENTAL
Intervention: Patient portal intervention for menopause
Number of subjects: 0
Study: 33786515

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33786522

Group type: EXPERIMENTAL
Intervention: Behavioral lifestyle intervention
Number of subjects: 0
Study: 33786583

Group type: EXPERIMENTAL
Intervention: Duvelisib (Duv) and Venetoclax (Ven) combination
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Duvelisib (Duv)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Venetoclax (Ven)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 4
Study: 33786810

Group type: EXPERIMENTAL
Intervention: Circumcision devices
Number of subjects: 4812
Study: 33786812

Group type: EXPERIMENTAL
Intervention: Rituximab plus glucocorticoid
Number of subjects: 104

Group type: COMPARATOR
Intervention: Glucocorticoid alone
Number of subjects: 104
Study: 33786851

Group type: EXPERIMENTAL
Intervention: HDL-C levels (continuous covariate)
Number of subjects: 9323

Group type: EXPERIMENTAL
Intervention: HDL-C levels (fourth quartile)
Number of subjects: 9323